We are live on ! Find out more
RNAC icon

Cartesian Therapeutics
RNAC

66 hedge funds and large institutions have $66.5M invested in Cartesian Therapeutics in 2025 Q2 according to their latest regulatory filings, with 8 funds opening new positions, 22 increasing their positions, 19 reducing their positions, and 14 closing their positions.

New
Increased
Maintained
Reduced
Closed

16% more repeat investments, than reductions

Existing positions increased: 22 | Existing positions reduced: 19

0.75% less ownership

Funds ownership: 25.41% → 24.66% (-0.75%)

8% less funds holding

Funds holding: 72 → 66 (-6)

23% less capital invested

Capital invested by funds: $86.7M → $66.5M (-$20.2M)

43% less first-time investments, than exits

New positions opened: 8 | Existing positions closed: 14

Holders
66
Holders Change
-6
Holders Change %
-8.33%
% of All Funds
0.87%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
8
Increased
22
Reduced
19
Closed
14
Calls
$632K
Puts
–
Net Calls
+$632K
Net Calls Change
+$632K

Top Buyers

Rank Fund Capital Flow
1
6CM
683 Capital Management
New York
+$735K
2
Marshall Wace
Marshall Wace
United Kingdom
+$469K
3
Jacobs Levy Equity Management
Jacobs Levy Equity Management
New Jersey
+$440K
4
GCP
GSA Capital Partners
United Kingdom
+$264K
5
Renaissance Technologies
Renaissance Technologies
New York
+$208K

Top Sellers

Rank Fund Capital Flow
1
JP Morgan Chase
JP Morgan Chase
New York
-$2.01M
2
MB
MPM BioImpact
Massachusetts
-$1.12M
3
Citadel Advisors
Citadel Advisors
Florida
-$281K
4
AA
ALPS Advisors
Colorado
-$256K
5
Goldman Sachs
Goldman Sachs
New York
-$208K
Name Holding Trade Value Shares
Change 		Change in
Stake
Fidelity Investments
1
Fidelity Investments
Massachusetts
$24.3M -$61.7K -5,793 -0.2%
MB
2
MPM BioImpact
Massachusetts
$7.13M -$1.12M -104,772 -13%
BlackRock
3
BlackRock
New York
$6.79M -$205K -19,210 -3%
SL
4
Siren LLC
Connecticut
$5.85M – – –
Vanguard Group
5
Vanguard Group
Pennsylvania
$5.16M -$76.4K -7,171 -1%
EAM
6
Erste Asset Management
Austria
$2.7M – – –
6CM
7
683 Capital Management
New York
$2.28M +$735K +69,000 +46%
Geode Capital Management
8
Geode Capital Management
Massachusetts
$2.28M -$70K -6,573 -3%
State Street
9
State Street
Massachusetts
$2.02M -$73K -6,856 -3%
Citadel Advisors
10
Citadel Advisors
Florida
$1.26M -$281K -26,423 -18%
Northern Trust
11
Northern Trust
Illinois
$862K -$100K -9,393 -10%
Marshall Wace
12
Marshall Wace
United Kingdom
$859K +$469K +44,025 +114%
GCP
13
GSA Capital Partners
United Kingdom
$432K +$264K +24,811 +148%
Jacobs Levy Equity Management
14
Jacobs Levy Equity Management
New Jersey
$429K +$440K +41,317 New
Barclays
15
Barclays
United Kingdom
$319K +$174K +16,306 +113%
Morgan Stanley
16
Morgan Stanley
New York
$304K +$121K +11,363 +64%
FCH
17
Freestone Capital Holdings
Washington
$269K – – –
Bank of New York Mellon
18
Bank of New York Mellon
New York
$260K +$43.1K +4,044 +19%
Charles Schwab
19
Charles Schwab
California
$259K -$46.9K -4,400 -15%
N
20
Nuveen
North Carolina
$255K -$35.9K -3,372 -12%
IC
21
Ikarian Capital
Texas
$230K – – –
DFG
22
Delphi Financial Group
Delaware
$229K – – –
Renaissance Technologies
23
Renaissance Technologies
New York
$203K +$208K +19,500 New
TFCP
24
Twin Focus Capital Partners
Massachusetts
$197K +$42.6K +4,000 +27%
Royal Bank of Canada
25
Royal Bank of Canada
Ontario, Canada
$190K +$169K +15,915 +667%
1
2 3 4

RNAC Hedge Fund Activity: Q2 2025 in Review

66 of the 7,595 institutional investors tracked by Wall St. Rank reported a position in Cartesian Therapeutics (RNAC) for Q2 2025, worth a combined $66.5M — down 23% from $86.7M a quarter earlier.

Sellers outnumbered buyers: 14 funds closed out of RNAC and 8 opened new positions — a net loss of 6 holders — while 19 trimmed existing stakes and 22 added.

The largest buyer was 683 Capital Management, adding an estimated $735K. The largest seller was JP Morgan Chase, cutting an estimated $2.01M.

  • 66 institutional investors held Cartesian Therapeutics (RNAC) as of Q2 2025, down from 72 in Q1 2025.
  • Funds reported $66.5M of Cartesian Therapeutics stock for Q2 2025, down 23% quarter-over-quarter.
  • 8 funds opened new Cartesian Therapeutics positions in Q2 2025 and 14 closed out, a net change of -6 holders.
  • The largest Cartesian Therapeutics buyer in Q2 2025 was 683 Capital Management, an estimated $735K added.
  • The largest Cartesian Therapeutics seller in Q2 2025 was JP Morgan Chase, an estimated $2.01M sold.

Based on aggregated 13F filings for Q2 2025.